A Peptide Showdown: F.D.A. Scientists May Clash With R.F.K.’s Agenda
Christina Jewett and Dana G. Smith / nytimes - Agency scientists are advising against allowing widespread use of several peptide injections. Robert F. Kennedy Jr., the health secretary, has said people should be free to experiment.
AI Summary: Federal regulators have zeroed in on a set of peptide injections gaining traction among wellness influencers and endorsed by RFK Jr., prompting internal debates about safety, evidence and regulation. FDA scientists are reviewing the products' claims and potential risks, setting up a clash between celebrity-driven demand and the agency’s evidence-based caution.
Related Stories
US gray‑market peptides face scrutiny as FDA panel debate looms / 18 days
The peptide problem: Hype outruns evidence, researchers caution / 2 months
FDA clears AstraZeneca’s new blood-pressure drug baxdrostat / 2 months
FDA escalates push to withdraw Amgen’s Tavneos; Amgen updates label / 2 months
FDA weighs easing access to compounded peptides for patients / 3 months
FDA links eight deaths to Amgen’s Tavneos; scrutiny intensifies / 3 months
Denali drug receives accelerated approval for rare CNS indication / 3 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Rural Health, Supply Chain, Pharmaceuticals, Novo Nordisk and look for the RSS link.
StackHealth Time Machine